The Flaws and Human Harms of Animal Experimentation by Akhtar, Aysha
WellBeing International 
WBI Studies Repository 
10-2015 
The Flaws and Human Harms of Animal Experimentation 
Aysha Akhtar 
Oxford Centre for Animal Ethics 
Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/moreaexp 
 Part of the Animal Experimentation and Research Commons, Animal Studies Commons, and the 
Bioethics and Medical Ethics Commons 
Recommended Citation 
Akhtar, A. (2015). The flaws and human harms of animal experimentation. Cambridge Quarterly of 
Healthcare Ethics, 24(4), 407-419. doi:10.1017/S0963180115000079 
This material is brought to you for free and open access 
by WellBeing International. It has been accepted for 
inclusion by an authorized administrator of the WBI 
Studies Repository. For more information, please contact 
wbisr-info@wellbeingintl.org. 
 Cambridge Quarterly of Healthcare Ethics (2015),  24 , 407–419 .
 © Cambridge University Press 2015. This is an Open Access article, distributed under the terms of the Creative 
Commons Attribution licence (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted 
re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
doi:10.1017/S0963180115000079
407
 Special Section: Moving Forward in Animal Research Ethics 
 The Flaws and Human Harms of Animal 
Experimentation 
 AYSHA  AKHTAR 
 Abstract:  Nonhuman animal (“animal”) experimentation is typically defended by arguments 
that it is reliable, that animals provide suffi ciently good models of human biology and dis-
eases to yield relevant information, and that, consequently, its use provides major human 
health benefi ts. I demonstrate that a growing body of scientifi c literature critically assessing 
the validity of animal experimentation generally (and animal modeling specifi cally) raises 
important concerns about its reliability and predictive value for human outcomes and for 
understanding human physiology. The unreliability of animal experimentation across a wide 
range of areas undermines scientifi c arguments in favor of the practice. Additionally, I show 
how animal experimentation often signifi cantly harms humans through misleading safety 
studies, potential abandonment of effective therapeutics, and direction of resources away 
from more effective testing methods. The resulting evidence suggests that the collective 
harms and costs to humans from animal experimentation outweigh potential benefi ts and 
that resources would be better invested in developing human-based testing methods. 
 Keywords:  animal research ;  medical testing ;  human health ;  human ethics ;  drug development ; 
 animal ethics 
 Introduction 
 Annually, more than 115 million animals are used worldwide in experimentation 
or to supply the biomedical industry.  1  Nonhuman animal (hereafter “animal”) 
experimentation falls under two categories: basic (i.e., investigation of basic 
biology and human disease) and applied (i.e., drug research and development and 
toxicity and safety testing). Regardless of its categorization, animal experimentation 
is intended to inform human biology and health sciences and to promote the safety 
and effi cacy of potential treatments. Despite its use of immense resources, the ani-
mal suffering involved, and its impact on human health, the question of animal 
experimentation’s effi cacy has been subjected to little systematic scrutiny.  2  
 Although it is widely accepted that medicine should be  evidence based , animal 
experimentation as a means of informing human health has generally not been 
held, in practice, to this standard. This fact makes it surprising that animal experi-
mentation is typically viewed as the default and gold standard of preclinical testing 
and is generally supported without critical examination of its validity. A survey 
published in 2008 of anecdotal cases and statements given in support of animal 
experimentation demonstrates how it has not and could not be validated as a neces-
sary step in biomedical research, and the survey casts doubt on its predictive value.  3  
 I am deeply indebted to David DeGrazia, Tom Beauchamp, and John Pippin for their careful review 
and helpful comments. The opinions expressed here are those of the author and do not represent the 
offi cial position of the U.S. Food and Drug Administration or the U.S. government. 
 Aysha Akhtar, M.D., M.P.H., is a neurologist and preventive medicine specialist and Fellow at the 
Oxford Centre for Animal Ethics, Oxford, United Kingdom. 
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I show that animal experimentation is poorly predictive of human outcomes,  4  
that it is unreliable across a wide category of disease areas,  5  and that existing 
literature demonstrates the unreliability of animal experimentation, thereby 
undermining scientifi c arguments in its favor. I further show that the collective 
harms that result from an unreliable practice tip the ethical scale of harms and 
benefi ts against continuation in much, if not all, of experimentation involving 
animals.  6  
 Problems of Successful Translation to Humans of Data from Animal 
Experimentation 
 Although the unreliability and limitations of animal experimentation have 
increasingly been acknowledged, there remains a general confi dence within much 
of the biomedical community that they can be overcome.  7  However, three major 
conditions undermine this confi dence and explain why animal experimentation, 
regardless of the disease category studied, fails to reliably inform human health: 
(1) the effects of the laboratory environment and other variables on study out-
comes, (2) disparities between animal models of disease and human diseases, and
(3) species differences in physiology and genetics. I argue for the critical impor-
tance of each of these conditions.
 The Infl uence of Laboratory Procedures and Environments on Experimental Results 
 Laboratory procedures and conditions exert infl uences on animals’ physiology 
and behaviors that are diffi cult to control and that can ultimately impact research 
outcomes. Animals in laboratories are involuntarily placed in artifi cial environ-
ments, usually in windowless rooms, for the duration of their lives. Captivity 
and the common features of biomedical laboratories—such as artifi cial lighting, 
human-produced noises, and restricted housing environments—can prevent species-
typical behaviors, causing distress and abnormal behaviors among animals.  8  
Among the types of laboratory-generated distress is the phenomenon of conta-
gious anxiety.  9  Cortisone levels rise in monkeys watching other monkeys being 
restrained for blood collection.  10  Blood pressure and heart rates elevate in rats 
watching other rats being decapitated.  11  Routine laboratory procedures, such as 
catching an animal and removing him or her from the cage, in addition to the 
experimental procedures, cause signifi cant and prolonged elevations in animals’ 
stress markers.  12  These stress-related changes in physiological parameters caused 
by the laboratory procedures and environments can have signifi cant effects on test 
results.  13  Stressed rats, for example, develop chronic infl ammatory conditions and 
intestinal leakage, which add variables that can confound data.  14  
 A variety of conditions in the laboratory cause changes in neurochemistry, 
genetic expression, and nerve regeneration.  15  In one study, for example, mice were 
genetically altered to develop aortic defects. Yet, when the mice were housed in 
larger cages, those defects almost completely disappeared.  16  Providing further 
examples, typical noise levels in laboratories can damage blood vessels in animals, 
and even the type of fl ooring on which animals are tested in spinal cord injury 
experiments can affect whether a drug shows a benefi t.  17  
 In order to control for potential confounders, some investigators have called for 
standardization of laboratory settings and procedures.  18  One notable effort was 
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made by Crabbe et al. in their investigation of the potential confounding infl u-
ences of the laboratory environment on six mouse behaviors that are commonly 
studied in neurobehavioral experiments. Despite their “extraordinary lengths to 
equate test apparatus, testing protocols, and all possible features of animal hus-
bandry” across three laboratories, there were systematic differences in test results 
in these labs.  19  Additionally, different mouse strains varied markedly in all behav-
ioral tests, and for some tests the magnitude of genetic differences depended on 
the specifi c testing laboratory. The results suggest that there are important infl u-
ences of environmental conditions and procedures specifi c to individual laborato-
ries that can be diffi cult—perhaps even impossible—to eliminate. These infl uences 
can confound research results and impede extrapolation to humans. 
 The Discordance between Human Diseases and Animal Models of Diseases 
 The lack of suffi cient congruence between animal models and human diseases is 
another signifi cant obstacle to translational reliability. Human diseases are typically 
artifi cially induced in animals, but the enormous diffi culty of reproducing anything 
approaching the complexity of human diseases in animal models limits their useful-
ness.  20  Even if the design and conduct of an animal experiment are sound and stan-
dardized, the translation of its results to the clinic may fail because of disparities 
between the animal experimental model and the human condition.  21  
 Stroke research presents one salient example of the diffi culties in modeling 
human diseases in animals. Stroke is relatively well understood in its underlying 
pathology. Yet accurately modeling the disease in animals has proven to be an 
exercise in futility. To address the inability to replicate human stroke in animals, 
many assert the need to use more standardized animal study design protocols. 
This includes the use of animals who represent both genders and wide age ranges, 
who have comorbidities and preexisting conditions that occur naturally in humans, 
and who are consequently given medications that are indicated for human 
patients.  22  In fact, a set of guidelines, named STAIR, was implemented by a stroke 
roundtable in 1999 (and updated in 2009) to standardize protocols, limit the discrep-
ancies, and improve the applicability of animal stroke experiments to humans.  23  
One of the most promising stroke treatments later to emerge was NXY-059, which 
proved effective in animal experiments. However, the drug failed in clinical trials, 
despite the fact that the set of animal experiments on this drug was considered the 
poster child for the new experimental standards.  24  Despite such vigorous efforts, 
the development of STAIR and other criteria has yet to make a recognizable impact 
in clinical translation.  25  
 Under closer scrutiny, it is not diffi cult to surmise why animal stroke experi-
ments fail to successfully translate to humans even with new guidelines. Standard 
stroke medications will likely affect different species differently. There is little evi-
dence to suggest that a female rat, dog, or monkey suffi ciently reproduces the 
physiology of a human female. Perhaps most importantly, reproducing the preex-
isting conditions of stroke in animals proves just as diffi cult as reproducing stroke 
pathology and outcomes. For example, most animals don’t naturally develop sig-
nifi cant atherosclerosis, a leading contributor to ischemic stroke. In order to repro-
duce the effects of atherosclerosis in animals, researchers clamp their blood vessels 
or artifi cially insert blood clots. These interventions, however, do not replicate the 
elaborate pathology of atherosclerosis and its underlying causes. Reproducing human 
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diseases in animals requires reproducing the  predisposing diseases, also a formidable 
challenge. The inability to reproduce the disease in animals so that it is congru-
ent in relevant respects with human stroke has contributed to a high failure rate in 
drug development. More than 114 potential therapies initially tested in animals 
failed in human trials.  26  
 Further examples of repeated failures based on animal models include drug 
development in cancer, amyotrophic lateral sclerosis (ALS), traumatic brain injury 
(TBI), Alzheimer’s disease (AD), and infl ammatory conditions. Animal cancer 
models in which tumors are artifi cially induced have been the basic translational 
model used to study key physiological and biochemical properties in cancer onset 
and propagation and to evaluate novel treatments. Nevertheless, signifi cant limi-
tations exist in the models’ ability to faithfully mirror the complex process of 
human carcinogenesis.  27  These limitations are evidenced by the high (among the 
highest of any disease category) clinical failure rate of cancer drugs.  28  Analyses of 
common mice ALS models demonstrate signifi cant differences from human ALS.  29  
The inability of animal ALS models to predict benefi cial effects in humans with 
ALS is recognized.  30  More than twenty drugs have failed in clinical trials, and the 
only U.S. Food and Drug Administration (FDA)–approved drug to treat ALS is 
Riluzole, which shows notably marginal benefi t on patient survival.  31  Animal 
models have also been unable to reproduce the complexities of human TBI.  32  
In 2010, Maas et al. reported on 27 large Phase 3 clinical trials and 6 unpublished 
trials in TBI that all failed to show human benefi t after showing benefi t in animals.  33  
Additionally, even after success in animals, around 172 and 150 drug development 
failures have been identifi ed in the treatment of human AD  34  and infl ammatory 
diseases,  35  respectively. 
 The high clinical failure rate in drug development across all disease categories 
is based, at least in part, on the inability to adequately model human diseases in 
animals and the poor predictability of animal models.  36  A notable systematic 
review, published in 2007, compared animal experimentation results with clinical 
trial fi ndings across interventions aimed at the treatment of head injury, respira-
tory distress syndrome, osteoporosis, stroke, and hemorrhage.  37  The study found 
that the human and animal results were in accordance only half of the time. In 
other words, the animal experiments were no more likely than a fl ip of the coin to 
predict whether those interventions would benefi t humans. 
 In 2004, the FDA estimated that 92 percent of drugs that pass preclinical tests, 
including “pivotal” animal tests, fail to proceed to the market.  38  More recent anal-
ysis suggests that, despite efforts to improve the predictability of animal testing, 
the failure rate has actually increased and is now closer to 96 percent.  39  The main 
causes of failure are lack of effectiveness and safety problems that were not pre-
dicted by animal tests.  40  
 Usually, when an animal model is found wanting, various reasons are proffered 
to explain what went wrong—poor methodology, publication bias, lack of preex-
isting disease and medications, wrong gender or age, and so on. These factors 
certainly require consideration, and recognition of each potential difference between 
the animal model and the human disease motivates renewed efforts to eliminate 
these differences. As a result, scientifi c progress is sometimes made by such efforts. 
However, the high failure rate in drug testing and development, despite attempts 
to improve animal testing, suggests that these efforts remain insuffi cient to over-
come the obstacles to successful translation that are inherent to the use of animals. 
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Too often ignored is the well-substantiated idea that these models are, for reasons 
summarized here, intrinsically lacking in relevance to, and thus highly unlikely to 
yield useful information about, human diseases.  41  
 Interspecies Differences in Physiology and Genetics 
 Ultimately, even if considerable congruence were shown between an animal 
model and its corresponding human disease, interspecies differences in physiol-
ogy, behavior, pharmacokinetics, and genetics would signifi cantly limit the reli-
ability of animal studies, even after a substantial investment to improve such 
studies. In spinal cord injury, for example, drug testing results vary according to 
which species and even which strain within a species is used, because of numer-
ous interspecies and interstrain differences in neurophysiology, anatomy, and 
behavior.  42  The micropathology of spinal cord injury, injury repair mechanisms, 
and recovery from injury varies greatly among different strains of rats and mice. 
A systematic review found that even among the most standardized and method-
ologically superior animal experiments, testing results assessing the effectiveness 
of methylprednisolone for spinal cord injury treatment varied considerably among 
species.  43  This suggests that factors inherent to the use of animals account for some 
of the major differences in results. 
 Even rats from the same strain but purchased from different suppliers produce 
different test results.  44  In one study, responses to 12 different behavioral measures 
of pain sensitivity, which are important markers of spinal cord injury, varied 
among 11 strains of mice, with no clear-cut patterns that allowed prediction of 
how each strain would respond.  45  These differences infl uenced how the animals 
responded to the injury and to experimental therapies. A drug might be shown to 
help one strain of mice recover but not another. Despite decades of using animal 
models, not a single neuroprotective agent that ameliorated spinal cord injury in 
animal tests has proven effi cacious in clinical trials to date.  46  
 Further exemplifying the importance of physiological differences among species, 
a 2013 study reported that the mouse models used extensively to study human 
infl ammatory diseases (in sepsis, burns, infection, and trauma) have been mis-
leading. The study found that mice differ greatly from humans in their responses 
to infl ammatory conditions. Mice differed from humans in what genes were 
turned on and off and in the timing and duration of gene expression. The mouse 
models even differed from one another in their responses. The investigators con-
cluded that “our study supports higher priority to focus on the more complex 
human conditions rather than relying on mouse models to study human infl am-
matory disease.”  47  The different genetic responses between mice and humans are 
likely responsible, at least in part, for the high drug failure rate. The authors stated 
that every one of almost 150 clinical trials that tested candidate agents’ ability to 
block infl ammatory responses in critically ill patients failed. 
 Wide differences have also become apparent in the regulation of the same genes, 
a point that is readily seen when observing differences between human and mouse 
livers.  48  Consistent phenotypes (observable physical or biochemical characteris-
tics) are rarely obtained by modifi cation of the same gene, even among different 
strains of mice.  49  Gene regulation can substantially differ among species and may 
be as important as the presence or absence of a specifi c gene. Despite the high degree 
of genome conservation, there are critical differences in the order and function of 
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genes among species. To use an analogy: as pianos have the same keys, humans 
and other animals share (largely) the same genes. Where we mostly differ is in the 
way the genes or keys are expressed. For example, if we play the keys in a certain 
order, we hear Chopin; in a different order, we hear Ray Charles; and in yet a differ-
ent order, it’s Jerry Lee Lewis. In other words, the same keys or genes are expressed, 
but their different orders result in markedly different outcomes. 
 Recognizing the inherent genetic differences among species as a barrier to trans-
lation, researches have expressed considerable enthusiasm for genetically modi-
fi ed (GM) animals, including transgenic mice models, wherein human genes are 
inserted into the mouse genome. However, if a human gene is expressed in mice, 
it will likely function differently from the way it functions in humans, being 
affected by physiological mechanisms that are unique in mice. For example, a cru-
cial protein that controls blood sugar in humans is missing in mice.  50  When the 
human gene that makes this protein was expressed in genetically altered mice, 
it had the opposite effect from that in humans: it caused  loss of blood sugar control 
in mice. Use of GM mice has failed to successfully model human diseases and to 
translate into clinical benefi t across many disease categories.  51  Perhaps the pri-
mary reason why GM animals are unlikely to be much more successful than other 
animal models in translational medicine is the fact that the “humanized” or altered 
genes are still in nonhuman animals. 
 In many instances, nonhuman primates (NHPs) are used instead of mice or 
other animals, with the expectation that NHPs will better mimic human results. 
However, there have been suffi cient failures in translation to undermine this opti-
mism. For example, NHP models have failed to reproduce key features of 
Parkinson’s disease, both in function and in pathology.  52  Several therapies that 
appeared promising in both NHPs and rat models of Parkinson’s disease showed 
disappointing results in humans.  53  The campaign to prescribe hormone replace-
ment therapy (HRT) in millions of women to prevent cardiovascular disease was 
based in large part on experiments on NHPs. HRT is now known to  increase the 
risk of these diseases in women.  54  
 HIV/AIDS vaccine research using NHPs represents one of the most notable 
failures in animal experimentation translation. Immense resources and decades of 
time have been devoted to creating NHP (including chimpanzee) models of HIV. 
Yet all of about 90 HIV vaccines that succeeded in animals failed in humans.  55  
After HIV vaccine gp120 failed in clinical trials, despite positive outcomes in 
chimpanzees, a  BMJ article commented that important differences between NHPs 
and humans with HIV misled researchers, taking them down unproductive 
experimental paths.  56  Gp120 failed to neutralize HIV grown and tested in cell cul-
ture. However, because the serum protected chimpanzees from HIV infection, two 
Phase 3 clinical trials were undertaken  57  —a clear example of how expectations 
that NHP data are more predictive than data from other (in this case, cell culture) 
testing methods are unproductive and harmful. Despite the repeated failures, 
NHPs (though not chimpanzees or other great apes) remain widely used for HIV 
research. 
 The implicit assumption that NHP (and indeed any animal) data are reliable has 
also led to signifi cant and unjustifi able human suffering. For example, clinical trial 
volunteers for gp120 were placed at unnecessary risk of harm because of unfounded 
confi dence in NHP experiments. Two landmark studies involving thousands of 
menopausal women being treated with HRT were terminated early because of 
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increased stroke and breast cancer risk.  58  In 2003, Elan Pharmaceuticals was forced 
to prematurely terminate a Phase 2 clinical trial when an investigational AD vaccine 
was found to cause brain swelling in human subjects. No signifi cant adverse 
effects were detected in GM mice or NHPs.  59  
 In another example of human suffering resulting from animal experimentation, 
six human volunteers were injected with an immunomodulatory drug, TGN 1412, 
in 2006.  60  Within minutes of receiving the experimental drug, all volunteers suf-
fered a severe adverse reaction resulting from a life-threatening cytokine storm 
that led to catastrophic systemic organ failure. The compound was designed to 
dampen the immune system, but it had the  opposite effect in humans. Prior to this 
fi rst human trial, TGN 1412 was tested in mice, rabbits, rats, and NHPs with no ill 
effects. NHPs also underwent repeat-dose toxicity studies and were given 500 times 
the human dose for at least four consecutive weeks.  61  None of the NHPs mani-
fested the ill effects that humans showed almost immediately after receiving min-
ute amounts of the test drug. Cynomolgus and rhesus monkeys were specifi cally 
chosen because their CD28 receptors demonstrated similar affi nity to TGN 1412 as 
human CD28 receptors. Based on such data as these, it was confi dently concluded 
that results obtained from these NHPs would most reliably predict drug responses 
in humans—a conclusion that proved devastatingly wrong. 
 As exemplifi ed by the study of HIV/AIDS, TGN 1412, and other experiences,  62  
experiments with NHPs are not necessarily any more predictive of human responses 
than experiments with other animals. The repeated failures in translation from stud-
ies with NHPs belie arguments favoring use of  any nonhuman species to study 
human physiology and diseases and to test potential treatments. If experimentation 
using chimpanzees and other NHPs, our closest genetic cousins, are unreliable, how 
can we expect research using other animals to be reliable? The bottom line is that 
animal experiments, no matter the species used or the type of disease research 
undertaken, are highly unreliable—and they have too little predictive value to 
justify the resultant risks of harms for humans, for reasons I now explain. 
 The Collective Harms That Result from Misleading Animal Experiments 
 As medical research has explored the complexities and subtle nuances of biological 
systems, problems have arisen because the  differences among species along these 
subtler biological dimensions far outweigh the  similarities , as a growing body of 
evidence attests. These profoundly important—and often undetected—differences 
are likely one of the main reasons human clinical trials fail.  63  
 “Appreciation of differences” and “caution” about extrapolating results from 
animals to humans are now almost universally recommended. But, in practice, 
how does one take into account differences in drug metabolism, genetics, expres-
sion of diseases, anatomy, infl uences of laboratory environments, and species- and 
strain-specifi c physiologic mechanisms—and, in view of these differences, discern 
what is applicable to humans and what is not? If we cannot determine which 
physiological mechanisms in which species and strains of species are applicable to 
humans (even setting aside the complicating factors of different caging systems 
and types of fl ooring), the usefulness of the experiments must be questioned. 
 It has been argued that some information obtained from animal experiments is 
better than no information.  64  This thesis neglects how misleading information can 
be worse than no information from animal tests. The use of nonpredictive animal 
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experiments can cause human suffering in at least two ways: (1) by producing 
misleading safety and effi cacy data and (2) by causing potential abandonment of 
useful medical treatments and misdirecting resources away from more effective 
testing methods. 
 Humans are harmed because of misleading animal testing results. Imprecise 
results from animal experiments may result in clinical trials of biologically faulty 
or even harmful substances, thereby exposing patients to unnecessary risk and 
wasting scarce research resources.  65  Animal toxicity studies are poor predictors of 
toxic effects of drugs in humans.  66  As seen in some of the preceding examples 
(in particular, stroke, HRT, and TGN1412), humans have been signifi cantly harmed 
because investigators were misled by the safety and effi cacy profi le of a new drug 
based on animal experiments.  67  Clinical trial volunteers are thus provided with 
raised hopes and a false sense of security because of a misguided confi dence in 
effi cacy and safety testing using animals. 
 An equal if indirect source of human suffering is the opportunity cost of aban-
doning promising drugs because of misleading animal tests.  68  As candidate drugs 
generally proceed down the development pipeline and to human testing based 
largely on successful results in animals  69  (i.e., positive effi cacy and negative adverse 
effects), drugs are sometimes not further developed due to unsuccessful results in 
animals (i.e., negative effi cacy and/or positive adverse effects). Because much 
pharmaceutical company preclinical data are proprietary and thus publicly unavail-
able, it is diffi cult to know the number of missed opportunities due to misleading 
animal experiments. However, of every 5,000–10,000 potential drugs investigated, 
only about 5 proceed to Phase 1 clinical trials.  70  Potential therapeutics may be 
abandoned because of results in animal tests that do not apply to humans.  71  
Treatments that fail to work or show some adverse effect in animals because of 
species-specifi c infl uences may be abandoned in preclinical testing even if they 
may have proved effective and safe in humans if allowed to continue through the 
drug development pipeline. 
 An editorial in  Nature Reviews Drug Discovery describes cases involving two 
drugs in which animal test results from species-specifi c infl uences could have 
derailed their development. In particular, it describes how tamoxifen, one of the 
most effective drugs for certain types of breast cancer, “would most certainly have 
been withdrawn from the pipeline” if its propensity to cause liver tumor in rats 
had been discovered in preclinical testing rather than after the drug had been on 
the market for years.  72  Gleevec provides another example of effective drugs that 
could have been abandoned based on misleading animal tests: this drug, which is 
used to treat chronic myelogenous leukemia (CML), showed serious adverse effects 
in at least fi ve species tested, including severe liver damage in dogs. However, 
liver toxicity was not detected in human cell assays, and clinical trials proceeded, 
which confi rmed the absence of signifi cant liver toxicity in humans.  73  Fortunately 
for CML patients, Gleevec is a success story of predictive human-based testing. 
Many useful drugs that have safely been used by humans for decades, such as 
aspirin and penicillin, may not have been available today if the current animal 
testing regulatory requirements were in practice during their development.  74  
 A further example of near-missed opportunities is provided by experiments on 
animals that delayed the acceptance of cyclosporine, a drug widely and success-
fully used to treat autoimmune disorders and prevent organ transplant rejection.  75  
Its immunosuppressive effects differed so markedly among species that researchers 
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judged that the animal results limited any direct inferences that could be made to 
humans. Providing further examples, PharmaInformatic released a report describ-
ing how several blockbuster drugs, including aripiprazole (Abilify) and esome-
prazole (Nexium), showed low oral bioavailability in animals. They would likely not 
be available on the market today if animal tests were solely relied on. Understanding 
the implications of its fi ndings for drug development in general, PharmaInformatic 
asked, “Which other blockbuster drugs would be on the market today, if animal 
trials would have not been used to preselect compounds and drug-candidates for 
further development?”  76  These near-missed opportunities and the overall 96 percent 
failure rate in clinical drug testing strongly suggest the unsoundness of animal 
testing as a precondition of human clinical trials and provide powerful evidence 
for the need for a new, human-based paradigm in medical research and drug 
development. 
 In addition to potentially causing abandonment of useful treatments, use of an 
invalid animal disease model can lead researchers and the industry in the wrong 
research direction, wasting time and signifi cant investment.  77  Repeatedly, research-
ers have been lured down the wrong line of investigation because of information 
gleaned from animal experiments that later proved to be inaccurate, irrelevant, or 
discordant with human biology. Some claim that we do not know which benefi ts 
animal experiments, particularly in basic research, may provide down the road. 
Yet human lives remain in the balance, waiting for effective therapies. Funding 
must be strategically invested in the research areas that offer the most promise. 
 The opportunity costs of continuing to fund unreliable animal tests may impede 
development of more accurate testing methods. Human organs grown in the lab, 
human organs on a chip, cognitive computing technologies, 3D printing of human 
living tissues, and the Human Toxome Project are examples of new human-based 
technologies that are garnering widespread enthusiasm. The benefi t of using these 
testing methods in the preclinical setting over animal experiments is that they are 
based on  human biology. Thus their use eliminates much of the guesswork required 
when attempting to extrapolate physiological data from other species to humans. 
Additionally, these tests offer whole-systems biology, in contrast to traditional in 
vitro techniques. Although they are gaining momentum, these human-based tests 
are still in their relative infancy, and funding must be prioritized for their further 
development. The recent advancements made in the development of more predictive, 
human-based systems and biological approaches in chemical toxicological testing 
are an example of how newer and improved tests have been developed because of 
a shift in prioritization.  78  Apart from toxicology, though, fi nancial investment in 
the development of human-based technologies generally falls far short of investment 
in animal experimentation.  79  
 Conclusion 
 The unreliability of applying animal experimental results to human biology and 
diseases is increasingly recognized. Animals are in many respects biologically and 
psychologically similar to humans, perhaps most notably in the shared character-
istics of pain, fear, and suffering.  80  In contrast, evidence demonstrates that critically 
important physiological and genetic differences between humans and other 
animals can invalidate the use of animals to study human diseases, treatments, 
pharmaceuticals, and the like. In signifi cant measure, animal models specifi cally, 
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and animal experimentation generally, are inadequate bases for predicting clinical 
outcomes in human beings in the great bulk of biomedical science. As a result, 
humans can be subject to signifi cant and avoidable harm. 
 The data showing the unreliability of animal experimentation and the resultant 
harms to humans (and nonhumans) undermine long-standing claims that animal 
experimentation is necessary to enhance human health and therefore ethically jus-
tifi ed. Rather, they demonstrate that animal experimentation poses signifi cant 
costs and harms to human beings. It is possible—as I have argued elsewhere—that 
animal research is more costly and harmful, on the whole, than it is benefi cial to 
human health.  81  When considering the ethical justifi ability of animal experiments, 
we should ask if it is ethically acceptable to deprive humans of resources, oppor-
tunity, hope, and even their lives by seeking answers in what may be the wrong 
place. In my view, it would be better to direct resources away from animal experi-
mentation and into developing more accurate, human-based technologies. 
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